At present, there are few studies on the clinical remission rate of diabetes after one year discontinuation of oral hypoglycemic drugs after intensive treatment. HMS5552 is a kind of GKA hypoglycemic drug. This study intends to observe the clinical remission rate of diabetes mellitus, beta cell function and blood sugar fluctuation of patients with type 2 diabetes mellitus who have been treated with HMS5552 for 52W or 28W and whose glucose control is up to the standard.

Inclusion Criteria:

• Complete HMS5552 treatment and safety visit;
• HbA1c < 8.0% was detected in our laboratory;
• Researchers judged the stability of glucose control based on the data of subjects'visits during HMS5552 treatment and the indicators of our hospital;
• Subjects are able and willing to monitor peripheral blood sugar and regularity of diet and exercise;
• Willing to sign written informed consent and abide by the research program.

Exclusion Criteria:

• There was a state of illness in the subjects who could not complete the follow-up during the observation period.
• The researchers judged that subjects'compliance with HMS5552 was affected during treatment.

In this study, subjects with type 2 diabetes mellitus treated with HMS5552 were screened to meet the target of glucose control when they completed 52 or 28 weeks of HMS5552 treatment respectively.